Nuestra lista de correo. Espera aprobación.
Correo electrónico:
Consultar este grupo

lunes, 28 de agosto de 2017

Cost-effectiveness analysis of N95 respirators and medical masks to protect healthcare workers in China

Background: There are substantial differences between the costs of medical masks and N95 respirators. Cost-effectiveness analysis is required to assist decision-makers evaluating alternative healthcare worker (HCW) mask/respirator strategies. This study aims to compare the cost-effectiveness of N95 respirators and medical masks for protecting HCWs in Beijing, China.
Methods: We developed a cost-effectiveness analysis model utilising efficacy and resource use data from two cluster randomised clinical trials assessing various mask/respirator strategies conducted in HCWs in Level 2 and 3 Beijing hospitals for the 2008–09 and 2009–10 influenza seasons. The main outcome measure was the incremental cost-effectiveness ratio (ICER) per clinical respiratory illness (CRI) case prevented. We used a societal perspective which included intervention costs, the healthcare costs of CRI in HCWs and absenteeism costs.
Results: The incremental cost to prevent a CRI case with continuous use of N95 respirators when compared to medical masks ranged from US $490–$1230 (approx. 3000-7600 RMB). One-way sensitivity analysis indicated that the CRI attack rate and intervention effectiveness had the greatest impact on cost-effectiveness.
Conclusions: The determination of cost-effectiveness for mask/respirator strategies will depend on the willingness to pay to prevent a CRI case in a HCW, which will vary between countries. In the case of a highly pathogenic pandemic, respirator use in HCWs would likely be a cost-effective intervention.
Keywords: Cost-effectiveness, Economic evaluation, N95 respirator, Mask, Healthcare worker

Mukerji, Shohini et al. “Cost-Effectiveness Analysis of N95 Respirators and Medical Masks to Protect Healthcare Workers in China from Respiratory Infections.” BMC Infectious Diseases 17 (2017): 464. PMC. Web. 7 Aug. 2017.

Sigue este Blog en Facebook y Twitter

No hay comentarios.: